Ciprofloxacin Hydrocortisone Brand Name– Cipro HC
What is Ciprofloxacin Hydrocortisone
Ciprofloxacin hydrochloride and hydrocortisone are combined in a nonsterile otic suspension (Cipro(R) HC Otic) for the treatment of acute otitis externa in adult and pediatric patients over the age of 1 year due to susceptible strains of Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus.
Ciprofloxacin is a fluoroquinolone antibiotic with in vitro activity against a wide range of gram-positive and gram-negative microorganisms; topical use in the ear is not associated with ototoxicity.
Hydrocortisone is an anti-inflammatory corticosteroid and is included to aid in the resolution of the inflammatory response associated with the bacterial infection.
Cipro(R) HC Otic was approved by the FDA on February 10, 1998.
- otitis externa
- Proteus mirabilis
- Pseudomonas aeruginosa
- Staphylococcus aureus (MSSA)
- antimicrobial resistance
- hearing loss
- laboratory monitoring not necessary
- benzyl alcohol hypersensitivity
- corticosteroid hypersensitivity
- ear discharge
- fungal infection
- herpes infection
- latex hypersensitivity
- mycobacterial infection
- ophthalmic administration
- parenteral administration
- quinolone hypersensitivity
- tympanic membrane perforation
- viral infection
There are no drug interactions associated with Ciprofloxacin Hydrocortisone products.